Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pikangqibai monoclonal antibody in adolescents with moderate-to-severe plaque psoriasis
CTR20254365Phase 3Active
- Sponsor
- Innovent Biologics
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing pikangqibai monoclonal antibody with placebo (2 arms). Primary endpoints: Safety and tolerability, PASI 75 response rate and 1 more. Started Dec 2025; status: active.
02
Drugs
picankibart
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on CTR20254365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254365.